CDKL2 (cyclin-dependent kinase-like 2) is a serine-threonine kinase belonging to the CDKL family 1. Functionally, CDKL2 regulates ciliary architecture by controlling the length of the ciliary proximal segment through association with intraflagellar transport machinery and influencing kinesin motor distribution 2. At the cellular level, CDKL2 phosphorylates EB2 substrate and can partially compensate for CDKL5 function in the brain, suggesting functional overlap within the CDKL kinase family 3. Clinically, CDKL2 is implicated in both neurodevelopmental and malignant disorders. De novo CDKL2 variants act as dominant-negative alleles causing developmental delay, intellectual disability, childhood-onset epilepsy, dyspraxia, and speech deficits 1. In cancer, CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression via ZEB1/E-cadherin signaling, with elevated expression associated with shorter disease-free survival 4. Conversely, CDKL2 shows tumor-suppressive roles in hepatocellular carcinoma and clear cell renal cell carcinoma, where hypermethylation-induced downregulation and low expression respectively correlate with poor prognosis 56. In gastric cancer, CDKL2 expression correlates with HER2 status and overall survival 7. These findings indicate CDKL2 has context-dependent roles as either an oncogene or tumor suppressor.